Triple drug combination improves survival in advanced bowel cancer patients

Written by Mike Gregg, Future Science Group

Novel data from the BEACON CRC Phase III trial has shown for the first time that a combination of targeted therapies can improve survival of patients with advanced bowel cancer. The results, which  were recently presented at the ESMO World Congress on Gastrointestinal Cancer 2019 (3–6 July, Barcelona, Spain), revealed that triple therapy targeting BRAF mutations in progressive metastatic colorectal tumours significantly improved overall survival when compared to standard care. The results from the BEACON CRC Phase III trial suggest that the three-drug combination that includes encorafenib, binimetinib and cetuximab should replace chemotherapy in patients with metastatic colorectal cancer who have a...

To view the full article, please register now for access

It's completely free